Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro

Yaoxue Xuebao

Volumn 49, Issue 11, 2014, Pages 1547-1553

  Wang, Hui Qiang ^a   Ma, Lin Lin ^a   Jiang, Jian Dong ^a   Pang, Rui ^b   Chen, Yu Jun ^b   Li, Yu Huan ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Electric Power Research Institute   (China)

Author keywords

Cytopathic effect; MTT; QRT PCR; Recombinant human interferon alpha 2b; Respiratory virus

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA; ALPHA INTERFERON; ALPHA2B INTERFERON; RECOMBINANT PROTEIN; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CORONAVIRUS; FLUORESCENCE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IN VITRO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; PARAINFLUENZA VIRUS; PHARMACODYNAMICS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY VIRUS; DRUG EFFECTS; HUMAN; HUMAN PARAINFLUENZA VIRUS 1; INFLUENZA A VIRUS; INFLUENZA B VIRUS;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INTERFERON-ALPHA; PARAINFLUENZA VIRUS 1, HUMAN; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84922489880     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gao LL, Yu SY, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons a-2b nasal spray to prevent acute viral respiratory infections in military recruits [J]. Vaccine, 2010, 28:4445-4451.
2. Paranhos-Baccala G, Komurian-Pradel F, Richard N., et al. Mixed respiratory virus infections [J]. J Clin Virol, 2008, 43: 407-410.
3. Nguyen-Van-Tam JS, Sellwood C. Intervention strategies for emerging respiratory virus infections: policy and public health considerations [J]. Curr Opin Virol, 2013, 3: 192-198.
4. Shen Z, Chen Z, Li X., et al. Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection [J]. Clin Microbiol Infect, 2013, 20: O493-O500.
5. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges [J]. Annu Rev Med, 2013, 64: 189-202.
6. Chen HS, Zhang XQ. Antivirus Drug: Methods and Applications: Vol 20 [M]. Beijing: Chemical Industry Press, 2006: 328.
7. Yu DX, Chen Q, Zhang L.L., et al. A field trial of recombinant human interferon α-2b for nasal spray to prevent SARS and other respiratory viral infections [J]. Chin J Exp Clin Viro, 2005, 19: 216-219.
8. Fensterl V, Sen GC. Interferons and viral infections [J]. Biofactors, 2009, 35: 14-20.
9. Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections [J]. Handb Exp Pharmacol, 2009: 203-241.
10. Zu M, Zhou D, Gao L., et al. Evaluation of Chinese traditional patent medicines against influenza virus in vitro [J]. Acta Pharm Sin, 2010, 45: 408-412.
11. Zhang Q, Zhao QJ, Xiong R.S., et al. Research progress of anti-influenza virus agents [J]. Acta Pharm Sin, 2010, 45:289-299.
12. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions [J], J Biol Chem, 2007, 282: 20053-20057.
13. van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses [J]. Viruses, 2012, 4: 1438-1476.
14. Wang X, Hinson ER, Cresswell P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts [J]. Cell Host Microbe, 2007, 2: 96-105.
15. Liu Q, Ma J, Strayer D.R., et al. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment [J]. Expert Rev Anti Infect Ther, 2014, 12: 165-169.